Recursion reported further positive data from its Phase 1b/2 TUPELO trial of REC-4881 in FAP. After 12 weeks, 87% of patients (13 of 15) had reduced total polyp burden, with a 47% median reduction.
RXRX · Recursion Pharmaceuticals, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 57%
- Last earnings
- Nov 3, 2026
- Latest filing
- 10-Q · Nov 2
- Price history
- Apr 2021 to Nov 2026
Up next
Latest documents
Recursion presented Phase 2 REC-4881 data showing a 47% median polyp burden reduction in FAP patients after 12 weeks. Also, 85% of evaluable patients remained below baseline 12 weeks off treatment.
Recursion Pharmaceuticals priced 61,540,000 shares at $3.25, expects approximately $200 million gross proceeds, and expects its cash runway to extend into 2029. Sanofi optioned a development candidate, triggering a $10 million milestone payment.
Recursion Pharmaceuticals amended its Tempus AI agreement to extend the term from five to six years, eliminate convenience termination, and reduce accessible records. It granted Tempus an oncology license to TxFM Model for two years for a non-refundable $12,000,000 fee.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. Recursion advanced a previously unexplored neuroscience target with Genentech, reported durable REC-4881 Phase 2 activity ahead of an FDA-path update, obtained IND clearance for REC-7735 with a planned 2H26 trial start, and made progress with Sanofi; partner inflows exceed $500 million. The company lowered 2026 cash operating expense guidance to <$375 million and expects its cash runway to extend into early 2028, although quarterly revenue declined and operating cash use increased.
- + Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing evidence of novel-target discovery and validation.
- + REC-4881 produced a 43% median polyp-burden reduction after three months with durable off-treatment activity, and an FDA update is expected in 2H26.
- + REC-7735 received IND clearance and is expected to begin its Phase 1/2 ZINNIA study in 2H26.
- + REC-1245 continued Phase 1 dose escalation with predictable exposure and target engagement, with additional data expected in 2H26.
- − Second-quarter revenue declined to $7.7 million from $19.2 million because Roche and Genentech revenue was lower following project completions in the prior period.
- − Quarterly operating cash use increased to $105.9 million from $76.4 million.
- − Cash, cash equivalents and restricted cash declined to $556.8 million from $753.9 million at year-end 2025.
- − The safety and efficacy of the investigational medicines have not been established.
- − Pharmaceutical development carries a high risk of failure before or after regulatory approval.
- − REC-4881's FDA discussions remain focused on de-risking study design and determining the appropriate primary endpoint for clinical benefit.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| annual polyp-burden increase | 85% | annual | — |
| Cash Operating Expense non-GAAP | $271.5M | nine months ended September 30, 2026 | — |
| compounds screened to development candidate | 204 | 18 months | — |
| design predictions generated each week | 24M | each week | — |
| Diagnosed prevalence | 55,700 | US + EU5 | — |
| disease control rate | 91.7% | data cutoff: August 21, 2026 | — |
| Estimated prevalence | 67,100 | US + EU5 | — |
| fewer compounds synthesized vs. industry benchmarks | 90% | across the portfolio | — |
| Grade 1 or 2 | 21 | data cutoff: August 21, 2026 | — |
| Grade 3 TRAEs | 15.4% | Data Cutoff Date: 10-Sep-2026 | — |
| maintained reductions below baseline | 85% | Week 25 | — |
| maintained reductions below baseline 12 weeks off treatment | 92% | 12 weeks off treatment | — |
| median polyp burden reductions in the lower GI | 50% | After 12 weeks of treatment | — |
| median polyp burden reductions in the upper GI | 55% | After 12 weeks of treatment | — |
| median reduction in total polyp burden | 47% | after 12 weeks of treatment | — |
| oversubscribed follow-on completed | $200M | October 2026 | — |
| partial responses | 3 | Data Cutoff Date: 21-Aug-2026 | — |
| patients | 26 | data cutoff: August 21, 2026 | — |
| patients achieved ≥1-stage Spigelman downstaging | 6 | Week 13 | — |
| patients had TRAEs ≤ Grade 2 | 80.8% | Data Cutoff Date: 10-Sep-2026 | — |
| patients with a reduction in total polyp burden | 87% | after 12 weeks of treatment | — |
| patients with equal or greater reductions during the off-treatment period than during treatment | 6 | Week 25, after 12 weeks off-treatment | — |
| patients with lower GI polyp burden reduction | 82% | Data Cutoff Date: 10-Sep-2026 | — |
| patients with no TRAEs | 1 | data cutoff: August 21, 2026 | — |
| patients with polyps >5 mm at baseline with fewer polyps | 6 | after 12 weeks of treatment | — |
| patients with upper GI polyp burden reduction | 92% | Data Cutoff Date: 10-Sep-2026 | — |
| patients with ≥65% polyp burden reduction from baseline | 4 | Week 13 | — |
| polyp burden in the lower GI remained below baseline | 70% | Week 25 | — |
| POST-COLECTOMY | 37,200 | US + EU5 | — |
| potential small molecule discovery programs | 40 | to date | — |
| PRE-COLECTOMY | 18,500 | US + EU5 | — |
| proprietary data | 50 | as of 30-Sep-2026 | — |
| reduction in total polyp burden | 98% | Week 13 | — |
| reductions in total polyp burden | 87% | Week 13 | — |
| reductions of 65% or more | 65% | after 12 weeks of treatment | — |
| reductions of ≥98% | 98% | after 12 weeks of treatment | — |
| remained below baseline | 85% | Week 25, after 12 weeks off-treatment | — |
| safety-evaluable patients dosed at 4 mg | 26 | data cutoff in the expanded patient population | — |
| Total Addressable FAP market | $15B | ’26 | — |
| total partner inflows to date | $535M | to date | — |
| total upfront and milestone payments achieved from Sanofi under the collaboration | $144M | the third quarter ended September 30, 2026 | — |
| unconfirmed | 1 | data cutoff: August 21, 2026 | — |
| Cash as of September 30, 2026 | $561M | as of September 30, 2026 | — |
| Disease control rate across all doses at 8 weeks | 66.7% | 8 weeks | — |
| Cash operating expense (six months ended June 30, 2026) non-GAAP | $191M | six months ended June 30, 2026 | — |
| upfront and milestone payments from the Sanofi collaboration (cumulative) | $134M | Q2 2026 | — |
| upfront and milestones payments from the Roche and Genentech collaboration (cumulative) | $216M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RXRX
this stock
Recursion Pharmaceuticals, Inc.
|
$1.53B | -40.1% | +26.9% | — | 22.8% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 2, 2026
- This year
- 20
Recursion reported further positive data from its Phase 1b/2 TUPELO trial of REC-4881 in FAP. After 12 weeks, 87% of patients (13 of 15) had reduced total polyp burden, with a 47% median reduction.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RXRX | -23.1% | -33.8% | -32.1% | -39.2% | -40.1% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -14.5% | -24.6% | -23.0% | -30.5% | -41.3% |